Overall verdict
Sell
1.5/10
1-year performance
-96.82%
Score breakdown
Down 96.8% over 1 year, 0% of the 52-week range.
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers ;
TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma ; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases ; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases ; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH ; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease; and Akeso, Inc. for the treatment of hepatocellular carcinoma.
TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Sector
Health Care
Industry
Biotechnology
Primary listing
Hkex
China
CEO
Yongqian Wu
Founded
2014
Employees
123
Revenue / employee
0 HKD
Next earnings
November 26, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
217.20 HKD
52-week low
6.34 HKD
1-year performance
-96.82%
Declining
Year-to-date performance
-94.41%
Declining
Drawdown
-97.03%
Major drawdown
Position in the 52-week range
0% of range
Gross margin 88.0%, the company loses 738.1% of its revenue, ROIC -36.0%, ROE -36.1%.
Net margin
-738.11%
Negative
Sector -212.24%|S&P 13.35%
Gross margin
87.99%
Exceptional
Return on equity (ROE)
-36.11%
Negative
Sector -55.92%|S&P 16.98%
Return on invested capital (ROIC)
-36.02%
Negative
Free cash flow margin (FCF)
-699.91%
Negative
Growth
0.0/10Revenue (trailing 12 months)
40.1M HKD
Revenue growth (1y)
—
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
2.3Md HKD
Financial strength
5.3/10Cash covers 16482.6% of the debt, net debt/EBITDA 3.4x.
Net debt / EBITDA
3.4x
Stretched
Gearing (net debt / equity)
-104.68%
Net cash
Cash
1.1Md HKD
Cash / market cap
46.05%
Very solid
Cash / total debt
16482.60%
Net cash
Interest coverage
-2090.6x
Stretched
Net debt
-1.1Md HKD
Equity
1.0Md HKD
Closed daily candles, 17 months
Last close on November 20, 2026: 6.45 HKD
- MM207.89
- MM509.06
- MM20032.88
- RSI 1422.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-22.77%
200-day average slope, 3 months
-58.76%
50-day average slope, 1 month
-9.45%
Price structure
flat
Bullish RSI divergence
No
20-day volatility
2.85 % per day
Volatility change
-50.71%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.74 (1) | -0.74 (1) | 0 (1) | -300 (1) | -300 (1) |
| 2027 | -0.32 (1) | -0.32 (1) | 162 (1) | -130 (1) | -130 (1) |
Amounts in millions of CNY, EPS in CNY per share. In brackets, the number of analysts. Consensus as of July 9, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | 0.3x | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.4x | -12.2 % | -96.8 % |
